ADC Therapeutics share price logo

ADC Therapeutics

NYSE: ADCT

$1.13

+0.05

(+4.63%)

as on

ADC Therapeutics Stock Performance

as on October 3, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.06
    $1.14
    downward going graph

    6.19%

    Downside

    0.88%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.78
    $4.98
    downward going graph

    31.01%

    Downside

    340.71%

    Upside

    downward going graph

ADC Therapeutics share price movements today

Previous Close
$1.08
Open
$1.09
Volume
1.3M
Market Cap
$137.9M
Day's Low - High
$1.06 - $1.14
52 Week Low - High
$0.78 - $4.98

ADC Therapeutics Historical Returns

1 Month Return
-14.39 %
3 Month Return
-5.04 %
1 Year Return
-72.3 %
3 Year Return
+ 37.74 %
5 Year Return
-95.72 %

ADC Therapeutics Stock Fundamentals & Key Indicators

Check ADC Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$137.9M

EPS (TTM)

-0.6626

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.67

Industry PE ratio

-8.53

PEG Ratio

-0.02

EBITDA

-87.5M

Revenue (TTM)

78.8M

Profit Margin

88.75%

Return On Equity TTM

44.63%

ADC Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of ADC Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
ADC Therapeutics image
ADC Therapeutics
Buy$137.9M-95.72%-1.6788.75%0.00%
United Therapeutics image
United Therapeutics
Buy$24.5B191.39%19.0486.14%0.00%
Viatris image
Viatris
Buy$20.4B29.41%-48.8134.83%2.75%
Haleon PLC Sponsored ADR image
Haleon PLC Sponsored ADR
Buy$39.2BNA18.0765.57%2.27%
Zoetis image
Zoetis
Buy$28.9B-64.48%11.4170.87%3.02%
See all

Stock Returns calculator for ADC Therapeutics Stock including INR - Dollar returns

The ADC Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

ADC Therapeutics investment value today

Current value as on today

₹30,057

Returns

-₹69,943

(-69.94%)

Returns from ADC Therapeutics Stock

-₹72,304 (-72.3%)

Dollar Impact

₹2,361 (+2.36%)

Analyst Recommendation on ADC Therapeutics Stock

Based on 2 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 2 analysts, 50% of analysts recommend a 'BUY' rating for ADC Therapeutics. Average target price of $3.33

ADC Therapeutics Share Price Target

Get share price movements and forecasts by analysts on ADC Therapeutics.

What analysts predicted

66.07%UPSIDE

Target Price

$3.33

Current Price

$1.13

Analyzed by

2 Analysts

High

$5

Target

$3.33

Low

$2

ADC Therapeutics target price $3.33, a slight upside of 66.07% compared to current price of $1.13. According to 2 analysts rating.

Indian Investors' Interest in ADC Therapeutics Stock

Search interest for ADC Therapeutics Stock has increased by 10% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:10% versus previous 30 day period

ADC Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
18
17
18
16
23
18
16
23
20
19
Gross Profit
15
16
17
15
20
18
15
21
16
16
Operating Income
-33
-29
-35
-32
-28
-44
-30
-18
-25
-25
EBITDA
-32
-22
-29
-18
-25
-41
-27
6
-20
-45
Interest Expense
12
12
13
11
12
12
13
13
12
13
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-46
-36
-43
-31
-38
-55
-40
-6
-32
-16
Income Tax Expense
0
0
0
0
0
1
-
0
-
-
Net Income
-46
-36
-43
-30
-38
-56
-40
-6
-32
-16
Net Profit Margin
86.10%
93.01%
95.39%
91.89%
91.05%
95.56%
92.68%
92.63%
81.95%
87.80%

ADC Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
1
2
-
33
209
69
70
81
Gross Profit
-83
-116
2
-141
32
206
67
64
73
Operating Income
-91
-125
-119
-219
-261
-123
-165
-130
-108
EBITDA
-91
-122
-114
-218
-230
-107
-145
-102
-89
Interest Expense
-
-
0
4
18
36
46
50
51
Depreciation
0
0
1
0
2
2
3
3
1
Income Before Tax
-89
-122
-115
-245
-251
-156
-200
-157
-142
Income Tax Expense
0
0
0
0
-21
0
39
0
0
Net Income
-89
-123
-116
-246
-230
-157
-240
-157
-142
Net Profit Margin
-4643.76%
-10258.42%
100.00%
0.00%
95.89%
98.43%
96.36%
91.60%
90.57%

ADC Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-46
-36
-43
-30
-38
-56
-40
-6
-32
-16
Operating Cash Flow
-44
-32
-25
-21
-56
-24
-29
-31
-29
-11
Investing Cash Flow
0
0
0
0
0
-
0
0
0
0
Financing Cash Flow
0
98
0
-1
0
93
0
58
0
0
Change in Cash
-44
65
-25
-23
-56
69
-29
26
-30
-11

ADC Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-89
-123
-116
-246
-230
-155
-240
-157
-142
Operating Cash Flow
-74
-121
-121
-168
-233
-136
-118
-123
-141
Investing Cash Flow
-3
-2
-2
-2
-6
-2
-3
0
0
Financing Cash Flow
197
0
100
494
267
0
73
97
150
Change in Cash
119
-123
-23
323
27
-139
-47
-27
10

Global Institutional Holdings in ADC Therapeutics

Check out the Institutions with significant holdings in ADC Therapeutics.

Funds
Holdings
MUTUAL FUND SERIES TRUST
4.47%
iShares
4.11%
Fidelity Salem Street Trust
0.85%
Vanguard
0.57%
Marcia Venegas
0.46%
See all

ADC Therapeutics News & Key Events

  • img

    Today's Timeline - 04 June

    Thu, 08:13 PM

    -

    ADCT shares fell 53.4% despite positive study results due to safety concerns and adverse events in the experimental group.

Insights on ADC Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -32.96M → -16.56M (in $), with an average increase of 99.0% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 82.4% return, outperforming this stock by 44.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 72.7% return, outperforming this stock by 145.0%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 23.05M → 19.24M (in $), with an average decrease of 8.5% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ADCT stock has moved down by -11.0%

About ADC Therapeutics

ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
OrganisationADC Therapeutics
HeadquartersBiopole, Epalinges, VD, 1066, CH
IndustryBiotechnology
CEOAmeet Mallik

Key Management of ADC Therapeutics

Name

Title

Dr. Mohamed Zaki M.D., Ph.D.

Chief Medical Officer

Dr. David S. Ege Ph.D.

Chief Technical Officer

Ms. Nicole Riley

Head of Investor Relations & Corporate Communications

Ms. Kimberly Pope

Senior VP & Chief People Officer

Ms. Marcy Graham

Investor Relations Officer

Dr. Ameet Mallik M.B.A., M.S.

CEO & Director

Mr. Jose I. Carmona M.B.A.

Chief Financial Officer

Ms. Lisa Michelle Kallebo

Corporate Controller & Chief Accounting Officer

Mr. Peter J. Graham Esq.

Secretary and Chief Legal & Compliance Officer

Ms. Kristen Harrington-Smith

Chief Commercial Officer

FAQs

What is ADC Therapeutics share price today?

ADC Therapeutics share price today is $1.13 as on at the close of the market. ADC Therapeutics share today touched a day high of $1.14 and a low of $1.06.

What is the 52 week high and 52 week low for ADC Therapeutics share?

ADC Therapeutics share touched a 52 week high of $4.98 on and a 52 week low of $0.78 on . ADC Therapeutics stock price today i.e. is closed at $1.13,which is 77.31% down from its 52 week high and 44.95% up from its 52 week low.

What is ADC Therapeutics's market capitalisation today?

ADC Therapeutics market capitalisation is $0.00T as on .

How to invest in ADC Therapeutics Stock (ADCT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for ADC Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy ADC Therapeutics Stock (ADCT) from India?

Indian investors can start investing in ADC Therapeutics (ADCT) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in ADC Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on ADC Therapeutics share’s latest price of $1.13 as on October 3, 2026 at 8:45 am IST, you will get 8.8496 shares of ADC Therapeutics. Learn more about fractional shares .

What are the returns that ADC Therapeutics has given to Indian investors in the last 5 years?

ADC Therapeutics stock has given -95.72% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?